CXCL8 and thyroid cancer: Reparixin was demonstrated to reduce cell viability and stemness of thyroid cancer cells, suggesting that the inhibition of the CXCL8 signaling pathway by either CXC receptor antagonism (i.e., Reparixin) as well as by molecules inhibiting CXCL8 secretion or activity might represent a new strategy for thyroid cancer therapy [22, 31–33, 52].